Antisense Therapeutics reports that an analysis of brain lesion data from the Phase II study of the ATL1102 in patients with Multiple Sclerosis (MS) has shown that the ATL1102 significantly reduces the number of active MS lesions that convert to “Black Holes”, areas of nerve fibre loss or permanent tissue damage.
- The positive effect of ATL1102 on black holes suggests that along with its action in reducing the number of inflammatory lesions, ATL1102 may also be potentially neuroprotective.
The post hoc analysis was conducted by Dr Frederik Barkhof, Professor of Neuroradiology, Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, and co-author on the Limmroth et al Neurology publication.
Prof Barkhof said of the results; “Assessing the effect of MS treatments to prevent lesions evolving into so-called “Black Holes” is a relatively new manner to determine neuroprotection in MS. Reducing black holes signifies preservation of brain tissue and the slowing of MS disease progression. The positive effects observed with ATL1102 on black holes are encouraging and suggestive of ATL1102’s potential neuroprotective effects, which could be very important, particularly when contemplating the drug’s potential as a treatment for progressive forms of MS”.
The Company has filed a provisional patent application incorporating this new data while an abstract of the results is to be submitted for presentation at an MS scientific meeting this year.
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets.